MEXICO CITY--(BUSINESS WIRE)-- #Gilead--AIDS Healthcare Foundation (AHF), the world's largest HIV ca

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhil

GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, add

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it h

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper dr

Gilead Sciences NASDAQ: GILD executives outlined plans to expand the company's HIV prevention and tr

Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Tra

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the [url="]Pan American He

– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Countr

U.S. drugmaker Gilead Sciences said on Tuesday it had reached an agreement with the Pan American Hea

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agr

 - conference call

Bank of America Corp DE lessened its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 6.7% during th

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88%

Baird Financial Group Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by

Gilead Sciences (NASDAQ: GILD - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) are bo

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annu

Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference

Gilead Sciences NASDAQ: GILD CFO Andy Dickinson told attendees at the Cantor Global Healthcare Confe

HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the pr

Gilead Sciences, Inc. (GILD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined the company's priorities

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88%

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Opens State-of-the-Art Research Center to Advance the N

The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologic

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annual

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma

Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gil

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annu

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 m

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains

Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40

Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30)

Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfiz

California's highest court on Monday ruled in favor of Gilead Sciences GILD.O, in a case address

Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowe

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C comb

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Hu

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up t